Altre lingue Oncolys BioPharma Inc.

Azioni

4588

JP3202170001

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 12/07/2024			Variaz. 5gg	Var. 1 gen.
598 ^JPY	-0,50%		+9,12%	+5,47%

03/06	Medigen Biotechnology Corp. e Oncolys BioPharma iscrivono il primo partecipante allo studio clinico di Fase II avviato dallo sperimentatore	CI
09/02	Oncolys BioPharma Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Oncolys BioPharma Inc. announced that it expects to receive ¥2.2 million in funding	14/06
Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial	03/06
Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/02
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	07/02
Oncolys BioPharma : Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma	20/12
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine	20/12
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal Adenocarcinoma	07/11
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy	02/11
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	16/10/23
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	16/10/23
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin?? in Combination Therapy	10/08/23
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	04/08/23
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug	26/07/23
Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome	25/07/23
Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	24/07/23
Oncolys BioPharma Inc. announced that it expects to receive ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	07/07/23
ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma	06/06/23
Oncolys BioPharma Announces Results from an Investigator-Initiated Phase II Clinical Trial for Telomelysin™? (OBP-301) in Combination with Pembrolizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma	06/06/23
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023	12/05/23
Oncolys BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Oncolys BioPharma Inc.

Azioni

4588

JP3202170001

Altre lingue

Filtri